Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial
David Shannahoff-Khalsa, Rodrigo Yacubian Fernandes, Carlos A de B Pereira, John S March, James F Leckman, Shahrokh Golshan, Mário S R Vieira, Guilherme V Polanczyk, Euripedes C Miguel, Roseli G Shavitt, David Shannahoff-Khalsa, Rodrigo Yacubian Fernandes, Carlos A de B Pereira, John S March, James F Leckman, Shahrokh Golshan, Mário S R Vieira, Guilherme V Polanczyk, Euripedes C Miguel, Roseli G Shavitt
Abstract
Background: Obsessive-compulsive disorder (OCD) is often a life-long disorder with high psychosocial impairment. Serotonin reuptake inhibitors (SRIs) are the only FDA approved drugs, and approximately 50% of patients are non-responders when using a criterion of 25% to 35% improvement with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). About 30% are non-responders to combined first-line therapies (SRIs and exposure and response prevention). Previous research (one open, one randomized clinical trial) has demonstrated that Kundalini Yoga (KY) meditation can lead to an improvement in symptoms of obsessive-compulsive severity. We expand here with a larger trial. Design: This trial compared two parallel run groups [KY vs. Relaxation Response meditation (RR)]. Patients were randomly allocated based on gender and Y-BOCS scores. They were told two different (unnamed) types of meditation would be compared, and informed if one showed greater benefits, the groups would merge for 12 months using the more effective intervention. Raters were blind in Phase One (0-4.5 months) to patient assignments, but not in Phase Two. Main Outcome Measures: Primary outcome variable, clinician-administered Y-BOCS. Secondary scales: Dimensional Yale-Brown Obsessive Compulsive Scale (clinician-administered), Profile of Mood Scales, Beck Anxiety Inventory, Beck Depression Inventory, Clinical Global Impression, Short Form 36 Health Survey. Results: Phase One: Baseline Y-BOCS scores: KY mean = 26.46 (SD 5.124; N = 24), RR mean = 26.79 (SD = 4.578; N = 24). An intent-to-treat analysis with the last observation carried forward for dropouts showed statistically greater improvement with KY compared to RR on the Y-BOCS, and statistically greater improvement on five of six secondary measures. For completers, the Y-BOCS showed 40.4% improvement for KY (N = 16), 17.9% for RR (N = 11); 31.3% in KY were judged to be in remission compared to 9.1% in RR. KY completers showed greater improvement on five of six secondary measures. At the end of Phase Two (12 months), patients, drawn from the initial groups, who elected to receive KY continued to show improvement in their Y-BOCS scores. Conclusion: KY shows promise as an add-on option for OCD patients unresponsive to first line therapies. Future studies will establish KY's relative efficacy compared to Exposure and Response Prevention and/or medications, and the most effective treatment schedule. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01833442.
Keywords: Dimensional Yale-Brown Obsessive-Compulsive Scale; Yale-Brown Obsessive Compulsive Scale; anxiety/anxiety disorders; depression; mental health; mindfulness.
Copyright © 2019 Shannahoff-Khalsa, Fernandes, Pereira, March, Leckman, Golshan, Vieira, Polanczyk, Miguel and Shavitt.
Figures
References
- Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet (2009) 374:491–9. 10.1016/S0140-6736(09)60240-3
- Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry (2010) 15:53–63. 10.1038/mp.2008.94
- Hollander E, Kwon JH, Stein DJ, Broatch J, Rowland CT, Himelein CA. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry (1996) 57(Suppl 8):3–6.
- Fontenelle IS, Fontenelle LF, Borges MC, Prazeres AM, Range BP, Mendlowicz MV, et al. Quality of life and symptom dimensions of patients with obsessive-compulsive disorder. Psychiatry Res (2010) 179:198–203. 10.1016/j.psychres.2009.04.005
- Murray CJL, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability. In: Diseases, Injuries and Risk Factors in 1990 and projected 2020. Cambridge MA: Harvard University Press; (1996). p. 1–98.
- McKay D, Sookman D, Neziroglu F, Wilhelm S, Stein DJ, Kyrios M, et al. Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder. Psychiatry Res (2015) 225:236–46. 10.1016/j.psychres.2015.02.004
- Christensen H, Hadzi-Pavlovic D, Andrews G, Mattick R. Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol (1987) 55:701–11.
- Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol (1997) 1997 65: 44–52.
- Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol (2012) 15:1173–91. 10.1017/S1461145711001829
- Fineberg NA, Reghunandanan S, Simpson HB, Phillips KA, Richter MA, Matthews K, et al. Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res (2015) 227:114–25. 10.1016/j.psychres.2014.12.003
- Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev (2008) 1:CD001765. 10.1002/14651858.CD001765.pub3
- Shannahoff-Khalsa DS, Beckett LR. Clinical case report: efficacy of yogic techniques in the treatment of obsessive compulsive disorders. Int J Neurosci (1996) 85:1–17.
- Shannahoff-Khalsa D, Ray LE, Levine S, Gallen CC, Schwartz BJ, Sidorowich JJ. Randomized controlled trial of yogic meditation techniques for patients with obsessive compulsive disorders. CNS Spectrums: The Intern J Neuropsychiatric Med (1999) 4:34–46.
- Fossaluza V, Diniz JB, Pereira Bde B, Miguel EC, Pereira CA. Sequential allocation to balance prognostic factors in a psychiatric clinical trial. Clinics (Sao Paulo) (2009) 64:511–8.
- Shannahoff-Khalsa DS. Yogic techniques are effective in the treatment of obsessive compulsive disorders. In: Hollander, E, and Stein, D, editors. Obsessive-compulsive disorders: Diagnosis, etiology, and treatment. New York, NY: Marcel Dekker Inc. (1997). p. 283–329.
- Shannahoff-Khalsa DS. Kundalini Yoga meditation techniques in the treatment of obsessive compulsive and OC spectrum disorders. Brief Treat Crisis Intervention (2003) 3:369–82.
- Shannahoff-Khalsa DS. Kundalini Yoga meditation techniques in the treatment of obsessive compulsive and OC spectrum disorders. In: Albert, PD, and Roberts, R, editors. Social Workers’ Desk Reference., New York, NY: Oxford University Press (2008). p. 606–12.
- Shannahoff-Khalsa DS. Kundalini yoga meditation: techniques specific for psychiatric disorders, couples therapy, and personal growth. New York, London: W. W. Norton & Co. Inc. (2006).
- Shannahoff-Khalsa D. Sacred Therapies: The kundalini yoga meditation handbook for mental health. New York, London: W. W. Norton, Co., Inc. (2012).
- Benson H, Klipper MZ. The relaxation response. New York: Harper Torch; (2000).
- Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR. The Yale-brown obsessive compulsive scale. II. Validity Arch Gen Psychiatry (1989) 46:1012–6.
- Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry (1989) 46:1006–11.
- Rosario-Campos MC, Miguel EC, Quatrano S, Chacon P, Ferrao Y, Findley D, et al. The Dimensional yale-brown obsessive–compulsive scale (DY-BOCS): an instrument for assessing obsessive–compulsive symptom dimensions. Mol Psychiatry (2006) 11:495–504.
- Guy W. Clinical global impression. In: ECDEU Assessment manual for psychopharmacology. National Institute of Mental Health, P.H.S. US Department of Health and Human Services, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch., Rockville, MD: P.H.S. US Department of Health and Human Services; (1976).
- McNair D, Lorr M, Droppleman L. Profile of moods scale (revised 1992). Educational and industrial testing service. San Diego, CA: Educational and Industrial Testing Services; (1992).
- Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol (1988) 56:893–7.
- Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry (1961) 4:561–71.
- Cunha J. Manual da versa o em Portugue’s das escalas de Beck. Sao Paulo: Casa do Psico’ logo; (2001).
- Ware JE, Kosinski M, Dewey JE. How to score version two of the SF-36 health survey. Lincoln, RI: QualityMetric, Incorporated; (2000).
- Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull (1986) 22:343–81.
- Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, et al. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder. Mol Psychiatry (2014) 19:1025–30. 10.1038/mp.2014.50
- Shannahoff-Khalsa DS. Stress technology medicine, a new paradigm for stress and considerations for self-regulation. In: Brown, M, Koob, G, and Rivier, C, editors. Stress: Neurobiology and Neuroendocrinology. New York: Marcel Dekker Inc. (1991). p. 647–86.
- Shannahoff-Khalsa D. Meditation: the science and the art. In: Ramachandran, VS, editor. The encyclopedia of human behavior. San Diego, CA: Academic Press (2012). p. 576–84.
- Shannahoff-Khalsa DS. Selective unilateral autonomic activation: implications for psychiatry. CNS Spectrum: The Intern J Neuropsychiatric Med (2007) 12:625–34.
- Shannahoff-Khalsa DS. Psychophysiological states: the ultradian dynamics of mind-body interactions. in International Review of Neurobiology. London, New York, San Diego: Academic Press/Elsevier; (2008).
- Bhat S, Varambally S, Karmani S, Govindaraj R, Gangadhar BN. Designing and validation of a yoga-based intervention for schizophrenia. Int Rev Psychiatry (2016) 28:327–33. 10.3109/09540261.2016.1170001
- Key BL, Rowa K, Bieling P, McCabe R, Pawluk EJ. Mindfulness-based cognitive therapy as an augmentation treatment for obsessive-compulsive disorder. Clin Psychol Psychother (2017) 24:1109–20. 10.1002/cpp.2076
Source: PubMed